The current standard therapy of epithelial ovarian cancer (EOC) is the combination of
surgery (primary cytoreductive surgery or interval cytoreductive surgery) and platinum-based …

In the Part I, we have discussed the background of CA125 and the development of anti-
CA125 monoclonal antibody (MAb) to highlight the potential role of CA125 and anti-CA125 …

Ovarian cancer has a high case fatality rate, but patients who have no visible residual
disease after surgery have a relatively good prognosis. The presence of any cancer cells left …

Objective To investigate the effect of treatment with neoadjuvant chemotherapy (NACT)
followed by interval debulking surgery (IDS), versus primary debulking surgery (PDS), on …

Contemporary population‐based data on ovarian cancer survival using current subtype
classifications and by surgical status are sparse. We evaluated 1‐, 3‐, 5‐and 7‐year relative …

Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular
features compared to other ovarian cancer types. The relationship between common …

Background Ovarian cancer is the seventh most common cancer among women and the
leading cause of death in women with gynaecological malignancies. Opinions differ …

Background The optimal number of neoadjuvant chemotherapy cycles in patients with
advanced ovarian cancer is still disputed. Objective To evaluate the impact of the number of …

Simple Summary Bevacizumab was approved by the European Medicines Agency in
December 2011 and by the Food and Drug Administration in June 2018 as a treatment for …

Abstract Purpose of Review Summarize the writings published in the last 5 years on the
management of surgery in the first line of treatment for advanced ovarian cancer. Recent …